Yoshimoto T, Naruse M, Naruse K, Shionoya K, Tanabe A, Tanaka M, Hagiwara H, Hirose S, Muraki T, Demura H
Department of Medicine, Tokyo Women's Medical College, Japan.
Biochem Biophys Res Commun. 1995 Nov 13;216(2):535-9. doi: 10.1006/bbrc.1995.2655.
Although the vasorelaxation by natriuretic peptide (NP) is much less potent in the vein than in the artery, mechanism underlying the phenomenon remains unknown. Since NP receptor consists of three subtypes with different functions, we determined the mRNA level of each NP receptor subtype in the artery and vein by ribonuclease protection assay. In the aorta, NP-A receptor related to the biological action of NP was the predominant form. By contrast, NP-C receptor related mainly to the clearance of NP was the predominant form in the inferior vena cava: NP-C mRNA level was about two fold higher than in the aorta, while both NP-A and NP-B receptor mRNA levels were about half of that in the aorta. These results provide the molecular basis for the different biological response to NP in the artery and vein. Differential gene expression of NP receptor subtype could be an important determinant of the biological actions of NP.
尽管利钠肽(NP)引起的血管舒张在静脉中的作用远不如在动脉中显著,但其背后的机制仍不清楚。由于NP受体由三种功能不同的亚型组成,我们通过核糖核酸酶保护试验测定了动脉和静脉中各NP受体亚型的mRNA水平。在主动脉中,与NP生物学作用相关的NP-A受体是主要形式。相比之下,主要与NP清除相关的NP-C受体是下腔静脉中的主要形式:NP-C mRNA水平比主动脉中高约两倍,而NP-A和NP-B受体mRNA水平约为主动脉中的一半。这些结果为动脉和静脉对NP的不同生物学反应提供了分子基础。NP受体亚型的差异基因表达可能是NP生物学作用的重要决定因素。